Evidence map›Paper›PMID 40274891›Full record

ArticleScientific reports2025

Rational design of synthetic antimicrobial peptides based on the Escherichia coli ShoB toxin.

Ingvill Pedersen Sæbø, Emma Dyhr, Ida Mathilde Marstein Riisnæs, Henrik Franzyk, Magnar Bjørås, James Alexander Booth, Emily Helgesen

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ingvill Pedersen SæbøDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Emma DyhrDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ida Mathilde Marstein RiisnæsDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Henrik FranzykDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Magnar BjøråsDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway.
James Alexander BoothDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway. james.booth@ntnu.no.
Emily HelgesenDepartment of Microbiology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway. emily.helgesen@ous-research.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic resistance is an escalating global concern, necessitating the development of novel antibiotics with unique mechanisms of action, and preferably also with a lowered propensity for resistance development. Type-I Toxin-Antitoxin (TA) systems that are ubiquitous in bacterial genomes consist of a genetic toxin element encoding a hydrophobic peptide and an antitoxin element producing an sRNA that inhibits the toxin translation. Although the biological roles of these membrane-associated toxins remain incompletely understood, their inherent lethality upon overexpression suggests a potential as antimicrobial agents. In this study, we explore the ShoB toxin from the shoB-ohsC TA system in Escherichia coli (E. coli) as a basis for designing synthetic antimicrobial peptides for exogenous delivery. We demonstrate that ShoB-derived peptides can retain antimicrobial efficacy when modified into shorter, cationic analogs with enhanced solubility. Our most promising hits exhibit rapid bactericidal action and frequency of resistance within E. coli cultures indicate a limited tendency for resistance development. These findings highlight that type-I TA systems constitute a novel source of potential peptide-based antibiotics, thereby offering an alternative largely unexplored strategy to combat antibiotic-resistant bacterial infections.

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesBacterial ToxinsEscherichia coliEscherichia coli ProteinsDrug DesignMicrobial Sensitivity TestsToxin-Antitoxin SystemsAnti-Bacterial AgentsAntimicrobial PeptidesBacterial ToxinsEscherichia coli ProteinsAntibacterial efficacyAntimicrobial resistancePeptide antibiotic developmentPeptide designSynthetic antimicrobial peptidesType-I Toxin-Antitoxin systems

Identifiers

PMID40274891
PMCPMC12022103

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.